Oncolytics Biotech Inc T.ONC

Re medical vs business buckhenry

[canadafan]

First buckhenry was creator of " get smart"; a great & fun TV series from the 1960s
doubt that is you. As he died 2 yrs ago.
moving on...
The medical, clinical discussions are very important & need to be understood. That being to appreciate the $$$ value potential of the company.
Onc is a biotech, with Pelareorep as its only product.
therfore , the potential end use of Pela becomes ONCs value.
day to day share price? 

it will go up & it will go down. notice the low daily volumes.
meaning 
Not a massive sell off based on anything other than some day traders cashing in.
Nor a massive buying 
why or why not?
Onc is clinically 3 months away from boom or bust.
That simple. Please see oncolytics biotech web investor presentation fo4 details.
Explained further. 

there are about 5-6 trials in progress. All in co- therapy , amongst Pfizer, Roche, Merck, & Incyte.
Thst we know of. They have also revealed they are in " confidential" trials with " multiple " pharma , looking towatrds a CAR-t , marketing deal.

Of the mentioned 5-6 trials, most significant is the Pancreatic cancer results revealed a few months ago.
That is with Roche. The original " run in" results were above expectations. They immediately ramped up enrolment.
The additional results from that expected to be presented near end of year.
should the additional patients respond as did the first few. Then Pelareorep becomes a blockbuster therapy.
The very long waited breast cancer, moving to phase 3 , with Pfizer is also expected to be announced near end of this year.
Either of those 2, move the value of Onc to a whole new league.
there is a possibility of failure ?
none of early data ( hence the medical lessons), indicate anything but great news ahead.
buy- out? Partnerships, are all hinging on the upcoming trial results.
The CAR-t, is a side story running on its own Merritt. 

All of the above changes zero, based on share price, today , tomorrow or ever.
Assuming the panc cancer trial brings the great results expected.
That would put Onc in a great position to negotiate either a longer term licensing deal/ parteship.
or outright buyout.
simialr takeover deals, for junior bio, with much less to offer, have recently been in the $5-$10billion range.
SP equating to about $16( usd)/ billion.
remenber they buy based on present value of future sales of the product, Not what SP is trading at.
hope this explains a few thIngs

[Buckhenry]

canadafan... I know a great deal about the science of pela but do not see the need to blabber on and on about this. you and others on here basically regurgitate the same data over and over. I dont need to hear about 4 year old data. again, I am more interested in the financial side but does not appear this is the site.

[westcoast1000]

Well, buck, the financial side is entirely driven by the science side. Nothing else matters except competitors which do not seem on the horizon in terms of the safety results and ease of use.

[Buckhenry]

based on the the stock price over the last 2 years they science is driving the financial down the toilet

[westcoast1000]

Well then I at least welcome you to stop reading and find someplace else to complain about what others are doing or reading. You are showing yourself pretty clearly here. No more needs to be said. 

[westcoast1000]

Fortunately, this site has an ignore button.

[Buckhenry]

but you said we are free to express our views or does the first amendment not apply here.

[canadafan]

d like to add yet another, seldom discussed side on ONC Pelareorep. Point: There are a handful of trials we have named & talked about repeatedly. How about the 100 or so people ( patients in trials), who wake up every day with hope. hope of progress from Pela & other combo treatments. Yet, perhaps at bed time sleep in fear of treatment failure. Do they own shares in Onc? Maybe, maybe not

[Lesalpes29]

IT'S a waiting game now. You can choose to do it patiently and holding your shares or sell because it's taking too much time or it's too risky. I'm on the wait side but I can be wrong of course!

[Buckhenry]

it's been a waiting game for over 20 years. if you get in biotechs looking for the instant pot of gold at the end of the rainbow you are going to be very disappointed.